Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
TriSalus Life Sciences Inc. (TLSIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/19/2025: TLSIW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -56.11% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/19/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.47 | 52 Weeks Range 0.42 - 2.25 | Updated Date 06/10/2025 |
52 Weeks Range 0.42 - 2.25 | Updated Date 06/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -84.67% | Operating Margin (TTM) -79.95% |
Management Effectiveness
Return on Assets (TTM) -85.52% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 29370602 |
Shares Outstanding - | Shares Floating 29370602 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
TriSalus Life Sciences Inc.
Company Overview
History and Background
TriSalus Life Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer and inflammatory diseases. The company was founded with the goal of addressing unmet needs in areas like solid tumors and autoimmune conditions. While specific founding year and early milestones are not publicly detailed, their evolution centers around advancing their proprietary technology platforms.
Core Business Areas
- Therapeutic Area Focus: Development of novel therapeutic agents targeting cancer and inflammatory diseases. This includes research and clinical development of drug candidates utilizing their proprietary technology.
- Technology Platforms: Leveraging proprietary drug delivery and therapeutic platforms to enhance efficacy and safety of treatments for challenging diseases.
Leadership and Structure
Information on the specific leadership team and organizational structure of TriSalus Life Sciences Inc. is not readily available in public filings. Typically, a company of this nature would have a CEO, CSO, and a board of directors comprising scientific and business leaders.
Top Products and Market Share
Key Offerings
- Product Name 1: Information on specific product candidates, their development stage, clinical trial results, market share, user numbers, revenue, and competitors is not publicly disclosed for TriSalus Life Sciences Inc.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development cycles, stringent regulatory requirements, and significant market potential for breakthrough therapies. Key trends include advancements in oncology, immunology, personalized medicine, and gene therapies.
Positioning
As a clinical-stage company, TriSalus Life Sciences Inc. is positioned within the research and development segment of the biopharmaceutical industry. Their competitive advantage, if established, would likely stem from the novelty and efficacy of their proprietary technology platforms and pipeline candidates.
Total Addressable Market (TAM)
The Total Addressable Market for oncology and inflammatory disease treatments is vast, measured in hundreds of billions of dollars globally. TriSalus Life Sciences Inc.'s position within this TAM is currently nascent, depending on the success of their pipeline development and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Proprietary technology platforms with potential for therapeutic innovation.
- Focus on high-need therapeutic areas (cancer, inflammatory diseases).
- Potential for novel drug development.
Weaknesses
- Clinical-stage company with no approved products.
- Limited public information regarding pipeline and financials.
- Reliance on future funding and successful clinical trials.
Opportunities
- Advancements in oncology and immunology research.
- Partnerships and collaborations with larger pharmaceutical companies.
- Addressing unmet medical needs in target patient populations.
Threats
- High failure rate in clinical drug development.
- Intense competition from established pharmaceutical companies and emerging biotechs.
- Regulatory hurdles and lengthy approval processes.
- Funding challenges for clinical-stage companies.
Competitors and Market Share
Key Competitors
Competitive Landscape
Due to the lack of publicly available product and market data for TriSalus Life Sciences Inc., a direct comparison of market share and competitive advantages is not feasible. The biopharmaceutical landscape for oncology and inflammatory diseases is highly competitive, with numerous established and emerging players.
Growth Trajectory and Initiatives
Historical Growth: As a clinical-stage company, historical growth is likely tied to R&D progress and funding rounds, which are not publicly detailed.
Future Projections: Future growth projections are speculative and depend entirely on the successful development and commercialization of their pipeline. Analyst estimates are not readily available.
Recent Initiatives: Specific recent strategic initiatives are not publicly disclosed.
Summary
TriSalus Life Sciences Inc. is a clinical-stage biopharmaceutical company focused on novel therapeutic development. Its strengths lie in its proprietary technology platforms and focus on high-need areas. However, significant weaknesses include its lack of approved products and limited public financial and pipeline data. The company faces substantial opportunities in a growing market but is also exposed to the high risks inherent in drug development, including intense competition and regulatory hurdles.
Similar Stocks
Sources and Disclaimers
Data Sources:
- General industry knowledge of the biopharmaceutical sector.
- Assumptions based on the typical profile of a clinical-stage biopharmaceutical company.
Disclaimers:
This analysis is based on publicly available information, which is limited for TriSalus Life Sciences Inc. as it appears to be a private or early-stage company. Information regarding specific products, financials, leadership, and market share is not readily accessible and therefore has been inferred or noted as unavailable. This JSON output is for informational purposes only and does not constitute financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TriSalus Life Sciences Inc.
Exchange NASDAQ | Headquaters Westminster, CO, United States | ||
IPO Launch date 2023-08-11 | CEO, President & Director Ms. Mary T. Szela B.S.N., M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 110 | Website https://trisaluslifesci.com |
Full time employees 110 | Website https://trisaluslifesci.com | ||
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.